Phoenixin 14 ameloriates pancreatic injury in streptozotocin-induced diabetic rats by alleviating oxidative burden.
Zarife Nigâr Ozdemir-KumralEminenur SenHasan Basri YapiciNurullah AtakulOmer Faruk DomrukYusra AldagLeyla Semiha SenFatma Kanpalta MustafaoğluMeral YukselDilek AkakinCan ErzikGoncagul HaklarNeşe ImeryuzPublished in: The Journal of pharmacy and pharmacology (2022)
Phoenixin-14 (PNX) is a neuropeptide that has been shown to prevent oxidative damage and stimulates insulin secretion. We investigated the effects of PNX on pancreatic injury induced by streptozotocin (STZ), and nicotinamide (NAD). Male Sprague-Dawley rats, in control (C) and diabetic (STZ) groups, were treated with either saline, or PNX (0.45 nmol/kg, or 45 nmol/kg) daily for 3 days 1 week after STZ injection. Fasting blood glucose (FBG) and gastric emptying rate (GER) were measured. Tissue and blood samples were collected. PNX treatments prevented pancreatic damage and β cell loss. Increased luminol and lucigenin levels in the pancreas, ileum and liver tissues of STZ groups were alleviated by PNX treatment in pancreatic and ileal tissues. PNX0.45 decreased FBG without any change in insulin blood level and pancreatic mRNA. GER increased in all diabetic rats while PNX0.45 delayed GER only in the C group. PNX diminishes pancreatic damage and lowers FBG by reducing oxidative load.
Keyphrases
- diabetic rats
- oxidative stress
- blood glucose
- type diabetes
- gene expression
- glycemic control
- physical activity
- insulin resistance
- cell therapy
- mesenchymal stem cells
- single cell
- mass spectrometry
- risk factors
- high resolution
- endothelial cells
- high fat diet
- smoking cessation
- high speed
- replacement therapy
- wound healing
- study protocol